Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04394052
Recruiting Observational

Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II

NCT04394052 · tracked via the Priya Life Science France tracker
Sponsor
Central Hospital, Nancy, France
Phase
Observational
Started
2020-06-01
Last updated
2020-07-21

Condition(s) studied

Soft Tissue NeoplasmBone Neoplasm

Investigational drug(s) / intervention(s)

MR imaging

MR imaging: Medical imaging

Study summary

This study aims at evaluating the value of various artificial intelligence based techniques to improve the characterization and image post-processing for patients with musculoskeletal tumors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients suspected to have a bone or soft-tissue tumor referred for imaging for initial tumors characterization and staging. Exclusion Criteria: * Pregnancy * Breast feeding patients * Renal insufficiency * Contra indications to MRI or CT * Prior surgery or treatment to the evaluated lesion.

Primary outcome measure(s)

  • Lesion benignancy or malignancy — Performed up to 6 months after CT and Magnetic Resonance (MR) imaging
    Histologic determination of lesion aggressiveness (benign versus malignant) on core biopsy material

Trial sites (1)

FacilityCityRegionStatus
CHU-Nancy Nancy Lorraine Recruiting

More Central Hospital, Nancy, France trials in France

Implementation of Mobile Intensive Care Unit Ultrasound Based Management for Acute Dyspnea Starting soon
ADvanced ALzheimer Disease and Effects of Protologic and LAnguage Rehabilitation Tools in Nursing Home (ADALPA) Starting soon
One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy Active, not recruiting
A Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies Recruiting
French National Observatory on Infective Endocarditis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04394052 on ClinicalTrials.gov ↗ ← All trials in France